Emma Walmsley, GSK CEO (MediaPunch Inc/Alamy)

Up­dat­ed: GSK takes vic­to­ry lap with block­buster sales for RSV vac­cine

GSK is look­ing to ride the mo­men­tum from its RSV vac­cine sales in­to 2024 and be­yond. Mean­while, it has cut three in­fec­tious dis­ease can­di­dates from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.